CN117045778A - 一种提高关节软骨健康的组合物及其生产工艺 - Google Patents
一种提高关节软骨健康的组合物及其生产工艺 Download PDFInfo
- Publication number
- CN117045778A CN117045778A CN202311264050.6A CN202311264050A CN117045778A CN 117045778 A CN117045778 A CN 117045778A CN 202311264050 A CN202311264050 A CN 202311264050A CN 117045778 A CN117045778 A CN 117045778A
- Authority
- CN
- China
- Prior art keywords
- calcium
- articular cartilage
- composition
- health
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001188 articular cartilage Anatomy 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000036541 health Effects 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 39
- 229940069978 calcium supplement Drugs 0.000 claims abstract description 26
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 25
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 240000007817 Olea europaea Species 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 235000015203 fruit juice Nutrition 0.000 claims abstract description 15
- 241000220317 Rosa Species 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 19
- 229960005069 calcium Drugs 0.000 claims description 19
- 239000011575 calcium Substances 0.000 claims description 19
- 229910052791 calcium Inorganic materials 0.000 claims description 19
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 238000007873 sieving Methods 0.000 claims description 18
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 235000001465 calcium Nutrition 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 7
- 239000008176 lyophilized powder Substances 0.000 claims description 7
- 239000003463 adsorbent Substances 0.000 claims description 6
- 238000007605 air drying Methods 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 6
- 229960005147 calcium acetate Drugs 0.000 claims description 6
- 239000001639 calcium acetate Substances 0.000 claims description 6
- 235000011092 calcium acetate Nutrition 0.000 claims description 6
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 6
- 229940047036 calcium ascorbate Drugs 0.000 claims description 6
- 239000011692 calcium ascorbate Substances 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 229960003563 calcium carbonate Drugs 0.000 claims description 6
- 235000010216 calcium carbonate Nutrition 0.000 claims description 6
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 6
- 239000001354 calcium citrate Substances 0.000 claims description 6
- 229960004256 calcium citrate Drugs 0.000 claims description 6
- 239000004227 calcium gluconate Substances 0.000 claims description 6
- 229960004494 calcium gluconate Drugs 0.000 claims description 6
- 235000013927 calcium gluconate Nutrition 0.000 claims description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 6
- 239000001527 calcium lactate Substances 0.000 claims description 6
- 229960002401 calcium lactate Drugs 0.000 claims description 6
- 235000011086 calcium lactate Nutrition 0.000 claims description 6
- 239000001362 calcium malate Substances 0.000 claims description 6
- 229940016114 calcium malate Drugs 0.000 claims description 6
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims description 6
- 235000011038 calcium malates Nutrition 0.000 claims description 6
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000292 calcium oxide Substances 0.000 claims description 6
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 6
- 229940087373 calcium oxide Drugs 0.000 claims description 6
- 235000012255 calcium oxide Nutrition 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 229960001714 calcium phosphate Drugs 0.000 claims description 6
- 235000011010 calcium phosphates Nutrition 0.000 claims description 6
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 6
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 235000019449 other food additives Nutrition 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 6
- 230000000750 progressive effect Effects 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 6
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 2
- 239000004150 EU approved colour Substances 0.000 claims 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 7
- 210000000988 bone and bone Anatomy 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 230000037118 bone strength Effects 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 239000003086 colorant Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000008355 cartilage degradation Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000968 fibrocartilage Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于医药技术领域,公开了一种提高关节软骨健康的组合物及其生产工艺,其组合物按重量百分比计包括以下组分:胶原蛋白肽5‑10%、玫瑰果籽提取物10‑20%、浓缩橄榄汁冻干粉1‑5%、VC0.1‑0.3%、果汁粉1‑3%、余量为钙补充剂。本发明以胶原蛋白肽、玫瑰果籽提取物、浓缩橄榄汁冻干粉为主料,辅以VC、果汁粉、钙补充剂等原料进行装袋,具有提高关节软骨健康的功效,既能防治和修复骨关节软骨损伤,又能增加骨质强度,适合各年龄段的关节炎患者使用,更适合中老年人群预防骨质疏松及骨关节软骨组织损伤或退行性病变,具有关节软骨再生修复功能。
Description
技术领域
本发明属于医药技术领域,具体涉及一种提高关节软骨健康的组合物及其生产工艺。
背景技术
关节软骨(articular cartilage)在关节中相连骨的表面,覆有一层关节软骨,或为透明软骨,或为纤维软骨。关节软骨朝向关节腔的面甚为光滑,便于骨与骨之间的运动。软骨本身具有弹性,所以能缓冲相连骨在走、跳及其它运动时的震动和冲击。此外,软骨的弹性及其变形能力,对于增加关节活动性也略有影响。关节软骨既无神经又无血管,它的营养主要由滑液和关节囊滑膜层周围的动脉分支供应。在这些胶原纤维之间,散在分布着软骨细胞,软骨细胞由浅层向深层逐渐由扁平样至椭圆或圆形的细胞组成,这些软骨细胞维持关节软骨的正常代谢。关节退行性病变又称骨质增生,即骨的退行性病变,是关节炎的一种表现。本病的致病因素主要是由于机械应力分布失衡或负载过度引起软骨磨损所致。由于社会职业的不断发展,软骨磨损导致产生的颈椎退行性病变、腰椎退行性病变、膝关节退行性病变越来越多,对于上述关节退行性病变市场上的产品极度缺乏,因此开发一种能解决上述问题的产品是非常必要的。
发明内容
本发明为了提高关节软骨健康,提供了一种组合物,该组合物既能够提供软骨组织合成的原料,又能提供具有消炎作用的营养成分;因此,该组合物既能预防关节炎,同时对受损的关节具有一定的消炎和修复作用。
本发明的技术方案是:一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:胶原蛋白肽10-20%、玫瑰果籽提取物10-20%、浓缩橄榄汁冻干粉5-10%、VC0.1-0.3%、果汁粉1-3%、余量为钙补充剂。
进一步的,按重量百分比计包括以下组分:胶原蛋白肽13-16%、玫瑰果籽提取物14-17%、浓缩橄榄汁冻干粉5-8%、VC0.1-0.3%、果汁粉1.5-2.5%、余量为钙补充剂。
进一步的,原料中钙补充剂是指碳酸钙、葡萄糖酸钙、乳酸钙、醋酸钙、柠檬酸钙、果糖酸钙、抗坏血酸钙、苹果酸钙、氨基酸螯合钙、氧化钙、磷酸钙、磷酸氢钙、乳钙中的一种或一种以上的组合。
进一步的,所述组合物还包括甜味剂、调味剂、稳定剂、着色剂或其他食品添加剂和/或药用辅料。
一种提高关节软骨健康的组合物的生产工艺,通过以下步骤进行制备:
(1) 将玫瑰果籽阴干后粉碎,通过20目筛网得到细粉,将细粉用70%~100%醇溶液,回流提取1.5-3h后,重复提取3次,在55-60℃下减浓缩,在阴暗低温及通风较好的地方晾干,制得醇中间提取物;
(2)将步骤(1)得到的醇中间提取物用得旋转蒸发仪旋蒸至无乙醇,加入20 mL纯水超声分散后抽滤,收集滤液;依次加入等体积的石油醚、水饱和正丁醇分别萃取3次;正丁醇层旋蒸至干,加入1-5 mL纯水超声溶解,D101大孔吸附树脂上样,依次以3倍体积的水、20%乙醇、80%乙醇、95%乙醇溶液分别进行洗脱;收集80%乙醇洗脱部分,旋蒸至干,得到玫瑰果籽提取物;
(3)取胶原蛋白肽、浓缩橄榄汁冻干粉、VC、果汁粉、钙补充剂分别粉碎过100目筛,与上述玫瑰果籽提取物按等量递加的方法置混合器中混合30-50分钟,至色泽均匀,置流化床制粒机中制粒,颗粒水份小于5%,30目筛整粒,混匀后装袋即得。
本发明的有益效果:本发明提供一种提高关节软骨健康的组合物及其生产工艺,以胶原蛋白肽、玫瑰果籽提取物、浓缩橄榄汁冻干粉为主料,辅以VC、果汁粉、钙补充剂等原料进行装袋;其中,VC能促进软骨再生,修复损伤的关节软骨,使软骨面变得平滑、厚实有弹性,恢复关节正常的生理和运动功能,VC能合成、补充关节滑液,润滑关节软骨表面,减少骨关节间的磨擦及震动,从而减缓软骨退化;胶原蛋白肽、玫瑰果籽提取物、浓缩橄榄汁冻干粉等是软骨营养物质,能够改善骨性关节炎,玫瑰果籽提取物还能够抑制骨关节炎软骨细胞过度凋亡,提高氨基聚糖合成、抑制软骨降解、促进关节滑膜和血管中的血栓流动、减轻滑膜炎。
具体实施方式
为使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施方式,进一步阐述本发明。
实施例1
一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:胶原蛋白肽13%、玫瑰果籽提取物17%、浓缩橄榄汁冻干粉5%、VC0.1%、果汁粉1.5%、余量为钙补充剂。
进一步的,原料中钙补充剂是指碳酸钙、葡萄糖酸钙、乳酸钙、醋酸钙、柠檬酸钙、果糖酸钙、抗坏血酸钙、苹果酸钙、氨基酸螯合钙、氧化钙、磷酸钙、磷酸氢钙、乳钙中的一种或一种以上的组合。
进一步的,所述组合物还包括甜味剂、调味剂、稳定剂、着色剂或其他食品添加剂和/或药用辅料。
一种提高关节软骨健康的组合物的生产工艺,通过以下步骤进行制备:
(1) 将玫瑰果籽阴干后粉碎,通过20目筛网得到细粉,将细粉用70%醇溶液,回流提取3h后,重复提取3次,在55℃下减浓缩,在阴暗低温及通风较好的地方晾干,制得醇中间提取物;
(2)将步骤(1)得到的醇中间提取物用得旋转蒸发仪旋蒸至无乙醇,加入20 mL纯水超声分散后抽滤,收集滤液;依次加入等体积的石油醚、水饱和正丁醇分别萃取3次;正丁醇层旋蒸至干,加入1-5 mL纯水超声溶解,D101大孔吸附树脂上样,依次以3倍体积的水、20%乙醇、80%乙醇、95%乙醇溶液分别进行洗脱;收集80%乙醇洗脱部分,旋蒸至干,得到玫瑰果籽提取物;
(3)取胶原蛋白肽、浓缩橄榄汁冻干粉、VC、果汁粉、钙补充剂分别粉碎过100目筛,与上述玫瑰果籽提取物按等量递加的方法置混合器中混合50分钟,至色泽均匀,置流化床制粒机中制粒,颗粒水份小于5%,30目筛整粒,混匀后装袋即得。
实施例2
一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:胶原蛋白肽14%、玫瑰果籽提取物16%、浓缩橄榄汁冻干粉6%、VC0.1%、果汁粉1.5%、余量为钙补充剂。
进一步的,原料中钙补充剂是指碳酸钙、葡萄糖酸钙、乳酸钙、醋酸钙、柠檬酸钙、果糖酸钙、抗坏血酸钙、苹果酸钙、氨基酸螯合钙、氧化钙、磷酸钙、磷酸氢钙、乳钙中的一种或一种以上的组合。
进一步的,所述组合物还包括甜味剂、调味剂、稳定剂、着色剂或其他食品添加剂和/或药用辅料。
一种提高关节软骨健康的组合物的生产工艺,通过以下步骤进行制备:
(1) 将玫瑰果籽阴干后粉碎,通过20目筛网得到细粉,将细粉用70%醇溶液,回流提取3h后,重复提取3次,在60℃下减浓缩,在阴暗低温及通风较好的地方晾干,制得醇中间提取物;
(2)将步骤(1)得到的醇中间提取物用得旋转蒸发仪旋蒸至无乙醇,加入20 mL纯水超声分散后抽滤,收集滤液;依次加入等体积的石油醚、水饱和正丁醇分别萃取3次;正丁醇层旋蒸至干,加入1-5 mL纯水超声溶解,D101大孔吸附树脂上样,依次以3倍体积的水、20%乙醇、80%乙醇、95%乙醇溶液分别进行洗脱;收集80%乙醇洗脱部分,旋蒸至干,得到玫瑰果籽提取物;
(3)取胶原蛋白肽、浓缩橄榄汁冻干粉、VC、果汁粉、钙补充剂分别粉碎过100目筛,与上述玫瑰果籽提取物按等量递加的方法置混合器中混合30-50分钟,至色泽均匀,置流化床制粒机中制粒,颗粒水份小于5%,30目筛整粒,混匀后装袋即得。
实施例3
一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:胶原蛋白肽15%、玫瑰果籽提取物15%、浓缩橄榄汁冻干粉7%、VC0.2%、果汁粉2%、余量为钙补充剂。
进一步的,原料中钙补充剂是指碳酸钙、葡萄糖酸钙、乳酸钙、醋酸钙、柠檬酸钙、果糖酸钙、抗坏血酸钙、苹果酸钙、氨基酸螯合钙、氧化钙、磷酸钙、磷酸氢钙、乳钙中的一种或一种以上的组合。
进一步的,所述组合物还包括甜味剂、调味剂、稳定剂、着色剂或其他食品添加剂和/或药用辅料。
一种提高关节软骨健康的组合物的生产工艺,通过以下步骤进行制备:
(1) 将玫瑰果籽阴干后粉碎,通过20目筛网得到细粉,将细粉用70%醇溶液,回流提取3h后,重复提取3次,在60℃下减浓缩,在阴暗低温及通风较好的地方晾干,制得醇中间提取物;
(2)将步骤(1)得到的醇中间提取物用得旋转蒸发仪旋蒸至无乙醇,加入20 mL纯水超声分散后抽滤,收集滤液;依次加入等体积的石油醚、水饱和正丁醇分别萃取3次;正丁醇层旋蒸至干,加入1-5 mL纯水超声溶解,D101大孔吸附树脂上样,依次以3倍体积的水、20%乙醇、80%乙醇、95%乙醇溶液分别进行洗脱;收集80%乙醇洗脱部分,旋蒸至干,得到玫瑰果籽提取物;
(3)取胶原蛋白肽、浓缩橄榄汁冻干粉、VC、果汁粉、钙补充剂分别粉碎过100目筛,与上述玫瑰果籽提取物按等量递加的方法置混合器中混合50分钟,至色泽均匀,置流化床制粒机中制粒,颗粒水份小于5%,30目筛整粒,混匀后装袋即得。
实施例
一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:胶原蛋白肽16%、玫瑰果籽提取物14%、浓缩橄榄汁冻干粉8%、VC0.2%、果汁粉2%、余量为钙补充剂。
进一步的,原料中钙补充剂是指碳酸钙、葡萄糖酸钙、乳酸钙、醋酸钙、柠檬酸钙、果糖酸钙、抗坏血酸钙、苹果酸钙、氨基酸螯合钙、氧化钙、磷酸钙、磷酸氢钙、乳钙中的一种或一种以上的组合。
进一步的,所述组合物还包括甜味剂、调味剂、稳定剂、着色剂或其他食品添加剂和/或药用辅料。
一种提高关节软骨健康的组合物的生产工艺,通过以下步骤进行制备:
(1) 将玫瑰果籽阴干后粉碎,通过20目筛网得到细粉,将细粉用70%醇溶液,回流提取3h后,重复提取3次,在60℃下减浓缩,在阴暗低温及通风较好的地方晾干,制得醇中间提取物;
(2)将步骤(1)得到的醇中间提取物用得旋转蒸发仪旋蒸至无乙醇,加入20 mL纯水超声分散后抽滤,收集滤液;依次加入等体积的石油醚、水饱和正丁醇分别萃取3次;正丁醇层旋蒸至干,加入1-5 mL纯水超声溶解,D101大孔吸附树脂上样,依次以3倍体积的水、20%乙醇、80%乙醇、95%乙醇溶液分别进行洗脱;收集80%乙醇洗脱部分,旋蒸至干,得到玫瑰果籽提取物;
(3)取胶原蛋白肽、浓缩橄榄汁冻干粉、VC、果汁粉、钙补充剂分别粉碎过100目筛,与上述玫瑰果籽提取物按等量递加的方法置混合器中混合50分钟,至色泽均匀,置流化床制粒机中制粒,颗粒水份小于5%,30目筛整粒,混匀后装袋即得。
对比例1
一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:胶原蛋白肽13%、玫瑰果籽提取物17%,VC0.1%、果汁粉1.5%、余量为钙补充剂。其他步骤与实施例1中相应的步骤相同。
对比例2
一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:胶原蛋白肽13%、浓缩橄榄汁冻干粉5%、VC0.1%、果汁粉1.5%、余量为钙补充剂。其他步骤与实施例2中相应的步骤相同。
对比例3
一种提高关节软骨健康的组合物,按重量百分比计包括以下组分:玫瑰果籽提取物17%、浓缩橄榄汁冻干粉5%、VC0.1%、果汁粉1.5%、余量为钙补充剂。
试验例1
以实施例1-4和对比例1-3的组合物进行试验,具体如下:
方法:通过临床募集符合膝关节骨性关节炎的患者服用治疗,根据服用药物前后的相关定性、定量指标,分析该制剂的临床疗效。
1、采集病例:根据膝关节骨关节炎的诊断标准筛选采集病例。
2、入组的70个患者每天服用本制剂2次,每次2克,每个患者治疗满1个疗程(3个月)。
3、比较入组患者治疗前后膝关节疼痛程度、骨关节炎严重程度、骨代谢相关、血清炎症因子水平以及不良反应发生情况:
(1)膝关节疼痛程度采用视觉模拟评分法(VAS)进行评定,分值范围0~10分,分值越高表明其疼痛程度越严重;
(2)膝关节骨性关节炎严重程度采用西安大略和麦克马斯特大学(The WesternOntario and McMaster UnveeNws , WOMAC)指数及高频超声相关数据评定,WOMAC分为24个条目,每个条目0-10分,分值越高表明关节炎越严重;高频超声测量膝关节内积液深度、髌上囊内滑膜厚度、滑膜内血流情况、内外侧半月板膨出程度、关节软骨厚度,积液程度深、滑膜增厚、滑膜内血流丰富、半月板膨出明显、关节软骨薄表明关节炎严重(开始前及服药6周、12周时测定);
(3)骨代谢相关采用双能X线骨密度测量单侧股骨颈的骨密度,全自动生化分析仪测定血清钙、磷、碱性磷酸酶(ALP)、25羟维生素D(25(OH)VitD)(开始前及服药12周时测定);
(4)血清炎症因子IL-1β、血清Ⅱ型胶原C-端肽(collagen type II C-telopeptide,CTX-II)均采用流式细胞法检测(开始前及服药12周时测定);
(5)不良反应包括恶心、呕吐、头晕、嗜睡等。
注:所有受试人员在受试期间均未服用关节炎药物及保健品。结果进行统计分析,p<0.05。
4、结果:从治疗2周起,实施例1-4的入组患者的临床症状均开始缓解,膝关节炎在治疗6周后临床症状具有明显缓解、12周后临床症状效果显著。50人中未发现不良反应。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (5)
1.一种提高关节软骨健康的组合物,其特征在于,按重量百分比计包括以下组分:胶原蛋白肽10-20%、玫瑰果籽提取物10-20%、浓缩橄榄汁冻干粉5-10%、VC0.1-0.3%、果汁粉1-3%、余量为钙补充剂。
2.根据权利要求1所述的一种提高关节软骨健康的组合物,其特征在于,按重量百分比计包括以下组分:胶原蛋白肽13-16%、玫瑰果籽提取物14-17%、浓缩橄榄汁冻干粉5-8%、VC0.1-0.3%、果汁粉1.5-2.5%、余量为钙补充剂。
3.根据权利要求1所述的一种提高关节软骨健康的组合物,其特征在于,原料中钙补充剂是指碳酸钙、葡萄糖酸钙、乳酸钙、醋酸钙、柠檬酸钙、果糖酸钙、抗坏血酸钙、苹果酸钙、氨基酸螯合钙、氧化钙、磷酸钙、磷酸氢钙、乳钙中的一种或一种以上的组合。
4.根据权利要求1所述的一种提高关节软骨健康的组合物,其特征在于,所述组合物还包括甜味剂、调味剂、稳定剂、着色剂或其他食品添加剂和/或药用辅料。
5.一种提高关节软骨健康的组合物的生产工艺,其特征在于,通过以下步骤进行制备:
(1) 将玫瑰果籽阴干后粉碎,通过20目筛网得到细粉,将细粉用70%~100%醇溶液,回流提取1.5-3h后,重复提取3次,在55-60℃下减浓缩,在阴暗低温及通风较好的地方晾干,制得醇中间提取物;
(2)将步骤(1)得到的醇中间提取物用得旋转蒸发仪旋蒸至无乙醇,加入20 mL纯水超声分散后抽滤,收集滤液;依次加入等体积的石油醚、水饱和正丁醇分别萃取3次;正丁醇层旋蒸至干,加入1-5 mL纯水超声溶解,D101大孔吸附树脂上样,依次以3倍体积的水、20%乙醇、80%乙醇、95%乙醇溶液分别进行洗脱;收集80%乙醇洗脱部分,旋蒸至干,得到玫瑰果籽提取物;
(3)取胶原蛋白肽、浓缩橄榄汁冻干粉、VC、果汁粉、钙补充剂分别粉碎过100目筛,与上述玫瑰果籽提取物按等量递加的方法置混合器中混合30-50分钟,至色泽均匀,置流化床制粒机中制粒,颗粒水份小于5%,30目筛整粒,混匀后装袋即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311264050.6A CN117045778A (zh) | 2023-09-28 | 2023-09-28 | 一种提高关节软骨健康的组合物及其生产工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311264050.6A CN117045778A (zh) | 2023-09-28 | 2023-09-28 | 一种提高关节软骨健康的组合物及其生产工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117045778A true CN117045778A (zh) | 2023-11-14 |
Family
ID=88657492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311264050.6A Withdrawn CN117045778A (zh) | 2023-09-28 | 2023-09-28 | 一种提高关节软骨健康的组合物及其生产工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117045778A (zh) |
-
2023
- 2023-09-28 CN CN202311264050.6A patent/CN117045778A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101248882B (zh) | 一种具有促进骨骼和骨关节健康的营养食品 | |
CN102302116B (zh) | 一种补钙、锁钙保健食品及其制备方法 | |
CN101695382A (zh) | 兼具改善骨骼及关节功能的补钙制剂 | |
CN101711786B (zh) | 一种用于缓解骨关节病、增强免疫力的制剂 | |
CN110403116A (zh) | 一种阿胶肽固体饮料及其制作方法 | |
CN110393728A (zh) | 乳酸杆菌属、其医药组合物及可食用组合物于治疗、预防或改善骨质疾病的用途 | |
CN102423487A (zh) | 一种骨关节保健组合物及其应用 | |
CN113332415A (zh) | 一种阿胶活性肽及其制备方法和应用 | |
CN101716194B (zh) | 一种多口味钙咀嚼片及其生产制作工艺 | |
KR20140075844A (ko) | 알긴산을 포함하는 골관절염 예방 또는 치료용 조성물 | |
CN104824677A (zh) | 一种增加骨密度的保健食品及其制备方法 | |
CN101455396A (zh) | 一种促进骨和骨关节健康的营养保健食品 | |
CN117045778A (zh) | 一种提高关节软骨健康的组合物及其生产工艺 | |
CN114365850A (zh) | 一种具有改善软骨健康的多肽组合物及其制备方法 | |
CN115969961A (zh) | 改善骨密度的钙、vd、蛋白肽组合物及其制备方法和应用 | |
KR20050111667A (ko) | 히아루론산, 글리코사미노글리칸 및/또는 콜라겐의생합성을 촉진하는 대두추출물 | |
CN108815505A (zh) | 提高中老年人骨密度和骨关节功能避免腰腿抽筋的组合物 | |
CN106820158B (zh) | 能引钙入骨且防止骨钙流失的补钙复剂及其制备方法 | |
CN104888192B (zh) | 一种增加骨密度的海参氨糖制剂及其生产方法 | |
KR102174835B1 (ko) | 보리잎 유래 다당 분획물을 함유하는 골 관련 질환의 개선, 예방 또는 치료용 조성물 | |
KR102191314B1 (ko) | 감잎 유래 다당 분획물을 함유하는 골 관련 질환의 개선, 예방 또는 치료용 조성물 | |
KR20060093918A (ko) | 숙지황과 오가피의 혼합 생약재 추출물 및 이를 유효성분으로 하는 골다공증 예방 및 치료용 조성물 | |
CN114009509A (zh) | 一种提高免疫力强筋骨助睡眠的配方奶粉及其制备方法 | |
JP2018002620A (ja) | 骨吸収抑制剤 | |
KR101529493B1 (ko) | 조골세포 분화 촉진과 파골세포의 분화 억제 활성을 갖는 자소자 추출물 및 상기 자소자 추출물을 유효성분으로 함유하는 제품 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20231114 |
|
WW01 | Invention patent application withdrawn after publication |